Last 12 months
Inside the activity.
0 purchase rows · 36 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 30 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 07, 2022 Filed Feb 9, 2022 22:00 UTC |
SZOSTAK M ANNEDirector
|
GiftCommon Stock | 660 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-003061 · doc1.xml · nonDerivative · entry 2 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust of M. Anne Szostak Disclosed balance after: 660 F2 · ownership.nature: The reporting person is the settlor of the Trust of M. Anne Szostak ("Trust") and the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares transferred to the Trust. Read SEC document |
| February 07, 2022 Filed Feb 9, 2022 22:00 UTC |
SZOSTAK M ANNEDirector
|
GiftCommon Stock | 660 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-003061 · doc1.xml · nonDerivative · entry 1 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 2021 Szostak IDEXX GRAT Disclosed balance after: 6,557 F1 · ownership.nature: The reporting person is the settlor and trustee of the 2021 Szostak IDEXX GRAT (the "GRAT"). The GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein. Read SEC document |
| January 28, 2022 Filed Feb 1, 2022 22:03 UTC |
JUNIUS DANIEL MDirector
|
GrantCommon Stock | 13 | $489.05 | $6,357.65 |
DisclosureSEC source: 0001567619-22-002287 · doc1.xml · nonDerivative · entry 1 JUNIUS DANIEL M · CIK 0001094159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,919 F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($6,562.50) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan. Read SEC document |
| January 28, 2022 Filed Feb 1, 2022 22:02 UTC |
ESSIG STUARTDirector
|
GrantCommon Stock | 49 | $489.05 | $23,963.45 |
DisclosureSEC source: 0001567619-22-002286 · doc1.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,149 F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($23,750.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan. Read SEC document |
| January 28, 2022 Filed Feb 1, 2022 22:01 UTC |
COLLINS AshaDirector
|
GrantCommon Stock | 41 | $489.05 | $20,051.05 |
DisclosureSEC source: 0001567619-22-002285 · doc1.xml · nonDerivative · entry 1 COLLINS Asha · CIK 0001832272 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178 F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($20,000.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan. Read SEC document |
| November 29, 2021 Filed Dec 1, 2021 22:01 UTC |
POLEWACZYK JAMES FExecutive Vice President
|
SaleCommon Stock | 4,595 | $633.00 | $2,908,635.00 |
DisclosureSEC source: 0001567619-21-021392 · doc1.xml · nonDerivative · entry 1 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,818.2845 F1 · balance_after: Updated to correct a scrivener's error in the Form 4 filed on August 25, 2021, which inadvertently reported the total amount of beneficially owned securities following the reported transaction as 19,494.2845 instead of 19,404.2845. Also includes 9 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on September 30, 2021. Read SEC document |
| November 29, 2021 Filed Dec 1, 2021 22:00 UTC |
Claflin Bruce L.Director
|
GiftCommon Stock | 1,560 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-021390 · doc1.xml · nonDerivative · entry 2 Claflin Bruce L. · CIK 0001403694 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Claflin Family Trust Disclosed balance after: 1,560 F1 · balance_after: On November 29, 2021, the reporting person contributed 1,560 shares to the Claflin Family Trust ('Trust'), of which the reporting person's spouse is the trustee, for the benefit of the reporting person's spouse and children. The reporting person disclaims beneficial ownership of the shares held in the Trust and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purpose. Read SEC document |
| November 29, 2021 Filed Dec 1, 2021 22:00 UTC |
Claflin Bruce L.Director
|
GiftCommon Stock | 1,560 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-021390 · doc1.xml · nonDerivative · entry 1 Claflin Bruce L. · CIK 0001403694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361 F1 · balance_after: On November 29, 2021, the reporting person contributed 1,560 shares to the Claflin Family Trust ('Trust'), of which the reporting person's spouse is the trustee, for the benefit of the reporting person's spouse and children. The reporting person disclaims beneficial ownership of the shares held in the Trust and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purpose. Read SEC document |
| November 19, 2021 Filed Jan 4, 2022 22:01 UTC |
AYERS JONATHAN WDirector
|
GiftCommon Stock | 560 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-000276 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 637,740 Read SEC document |
| November 12, 2021 Filed Nov 15, 2021 22:00 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 9,225 | Not disclosed Strike: $67.85 | Not disclosed |
DisclosureSEC source: 0001567619-21-020493 · doc1.xml · derivative · entry 5 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,225 shares Expires 2026-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy 45,535 shares of IDEXX Laboratories, Inc. common stock that vested in five annual installments beginning February 14, 2017. Read SEC document |
| November 12, 2021 Filed Nov 15, 2021 22:00 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
SaleCommon Stock | 2,273 | $621.26 | $1,412,126.03 |
DisclosureSEC source: 0001567619-21-020493 · doc1.xml · nonDerivative · entry 3 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,316.6426 F2 · price: This transaction was executed in multiple trades at prices ranging from $621.045 to $621.815. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 12, 2021 Filed Nov 15, 2021 22:00 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
SaleCommon Stock | 6,952 | $620.55 | $4,314,062.21 |
DisclosureSEC source: 0001567619-21-020493 · doc1.xml · nonDerivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,589.6426 F1 · price: This transaction was executed in multiple trades at prices ranging from $620.00 to $621.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 12, 2021 Filed Nov 15, 2021 22:00 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
Exercise / conversionCommon Stock | 9,225 | $67.85 | $625,916.25 |
DisclosureSEC source: 0001567619-21-020493 · doc1.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,541.6426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 22:29 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 20,000 | Not disclosed Strike: $67.85 | Not disclosed |
DisclosureSEC source: 0001567619-21-020098 · doc1.xml · derivative · entry 12 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,225 Underlying: Common Stock · 20,000 shares Expires 2026-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · price: Not applicable. F10 · derivative.exercise_date: Grant of option to buy 45,535 shares of IDEXX Laboratories, Inc. common stock that vested in five annual installments beginning February 14, 2017. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 22:29 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
SaleCommon Stock | 872 | $629.80 | $549,185.95 |
DisclosureSEC source: 0001567619-21-020098 · doc1.xml · nonDerivative · entry 10 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,316.6426 F9 · price: This transaction was executed in multiple trades at prices ranging from $629.46 to $630.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 22:29 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
SaleCommon Stock | 1,375 | $628.78 | $864,574.15 |
DisclosureSEC source: 0001567619-21-020098 · doc1.xml · nonDerivative · entry 9 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,188.6426 F8 · price: This transaction was executed in multiple trades at prices ranging from $628.34.10 to $629.33. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 22:29 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
SaleCommon Stock | 2,974 | $627.97 | $1,867,572.07 |
DisclosureSEC source: 0001567619-21-020098 · doc1.xml · nonDerivative · entry 8 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,563.6426 F7 · price: This transaction was executed in multiple trades at prices ranging from $627.32 to $628.32. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 22:29 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
SaleCommon Stock | 1,813 | $626.74 | $1,136,281.61 |
DisclosureSEC source: 0001567619-21-020098 · doc1.xml · nonDerivative · entry 7 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,537.6426 F6 · price: This transaction was executed in multiple trades at prices ranging from $626.10 to $627.09. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 22:29 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
SaleCommon Stock | 2,326 | $625.46 | $1,454,830.89 |
DisclosureSEC source: 0001567619-21-020098 · doc1.xml · nonDerivative · entry 6 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,350.6426 F5 · price: This transaction was executed in multiple trades at prices ranging from $625.06 to $626.05. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 22:29 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
SaleCommon Stock | 2,142 | $624.53 | $1,337,747.12 |
DisclosureSEC source: 0001567619-21-020098 · doc1.xml · nonDerivative · entry 5 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,676.6426 F4 · price: This transaction was executed in multiple trades at prices ranging from $624.04 to $625.03. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 22:29 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
SaleCommon Stock | 1,493 | $623.34 | $930,649.01 |
DisclosureSEC source: 0001567619-21-020098 · doc1.xml · nonDerivative · entry 4 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,818.6426 F3 · price: This transaction was executed in multiple trades at prices ranging from $622.97 to $623.965. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 22:29 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
SaleCommon Stock | 5,743 | $622.36 | $3,574,234.73 |
DisclosureSEC source: 0001567619-21-020098 · doc1.xml · nonDerivative · entry 3 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,311.6426 F2 · price: This transaction was executed in multiple trades at prices ranging from $621.79 to $622.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 22:29 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
SaleCommon Stock | 1,262 | $621.40 | $784,203.01 |
DisclosureSEC source: 0001567619-21-020098 · doc1.xml · nonDerivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,054.6426 F1 · price: This transaction was executed in multiple trades at prices ranging from $620.78 to $621.77. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 22:29 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
Exercise / conversionCommon Stock | 20,000 | $67.85 | $1,357,000.00 |
DisclosureSEC source: 0001567619-21-020098 · doc1.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,316.6426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 10, 2021 Filed Jan 4, 2022 22:01 UTC |
AYERS JONATHAN WDirector
|
GiftCommon Stock | 26 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-000276 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 638,300 Read SEC document |
| November 09, 2021 Filed Nov 10, 2021 22:31 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 6,310 | Not disclosed Strike: $67.85 | Not disclosed |
DisclosureSEC source: 0001567619-21-019740 · doc1.xml · derivative · entry 15 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,225 Underlying: Common Stock · 6,310 shares Expires 2026-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · price: Not applicable. F12 · derivative.exercise_date: Grant of option to buy 45,535 shares of IDEXX Laboratories, Inc. common stock that vested in five annual installments beginning February 14, 2017. Read SEC document |
| November 09, 2021 Filed Nov 10, 2021 22:31 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
SaleCommon Stock | 607 | $631.01 | $383,023.56 |
DisclosureSEC source: 0001567619-21-019740 · doc1.xml · nonDerivative · entry 12 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,316.6426 F11 · price: This transaction was executed in multiple trades at prices ranging from $631.005 to $631.49. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 09, 2021 Filed Nov 10, 2021 22:31 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
SaleCommon Stock | 5,703 | $630.13 | $3,593,652.49 |
DisclosureSEC source: 0001567619-21-019740 · doc1.xml · nonDerivative · entry 11 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,923.6426 F10 · price: This transaction was executed in multiple trades at prices ranging from $630.00 to $631.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 09, 2021 Filed Nov 10, 2021 22:31 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
Exercise / conversionCommon Stock | 6,310 | $67.85 | $428,133.50 |
DisclosureSEC source: 0001567619-21-019740 · doc1.xml · nonDerivative · entry 10 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,626.6426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 08, 2021 Filed Nov 10, 2021 22:31 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 10,000 | Not disclosed Strike: $67.85 | Not disclosed |
DisclosureSEC source: 0001567619-21-019740 · doc1.xml · derivative · entry 14 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,535 Underlying: Common Stock · 10,000 shares Expires 2026-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · price: Not applicable. F12 · derivative.exercise_date: Grant of option to buy 45,535 shares of IDEXX Laboratories, Inc. common stock that vested in five annual installments beginning February 14, 2017. Read SEC document |
| November 08, 2021 Filed Nov 10, 2021 22:31 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
SaleCommon Stock | 110 | $632.19 | $69,541.14 |
DisclosureSEC source: 0001567619-21-019740 · doc1.xml · nonDerivative · entry 9 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,316.6426 F9 · price: This transaction was executed in multiple trades at prices ranging from $632.01 to $632.36. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 08, 2021 Filed Nov 10, 2021 22:31 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
SaleCommon Stock | 743 | $631.39 | $469,121.66 |
DisclosureSEC source: 0001567619-21-019740 · doc1.xml · nonDerivative · entry 8 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,426.6426 F8 · price: This transaction was executed in multiple trades at prices ranging from $631.10 to $631.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 08, 2021 Filed Nov 10, 2021 22:31 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
SaleCommon Stock | 971 | $630.39 | $612,112.28 |
DisclosureSEC source: 0001567619-21-019740 · doc1.xml · nonDerivative · entry 7 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,169.6426 F7 · price: This transaction was executed in multiple trades at prices ranging from $630.03 to $630.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 08, 2021 Filed Nov 10, 2021 22:31 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
SaleCommon Stock | 2,094 | $629.63 | $1,318,446.27 |
DisclosureSEC source: 0001567619-21-019740 · doc1.xml · nonDerivative · entry 6 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,140.6426 F6 · price: This transaction was executed in multiple trades at prices ranging from $629.10 to $629.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 08, 2021 Filed Nov 10, 2021 22:31 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
SaleCommon Stock | 2,356 | $628.19 | $1,480,023.89 |
DisclosureSEC source: 0001567619-21-019740 · doc1.xml · nonDerivative · entry 5 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,234.6426 F5 · price: This transaction was executed in multiple trades at prices ranging from $628.01 to $628.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 08, 2021 Filed Nov 10, 2021 22:31 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
SaleCommon Stock | 1,326 | $627.41 | $831,941.55 |
DisclosureSEC source: 0001567619-21-019740 · doc1.xml · nonDerivative · entry 4 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,590.6426 F4 · price: This transaction was executed in multiple trades at prices ranging from $627.07 to $628.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 08, 2021 Filed Nov 10, 2021 22:31 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
SaleCommon Stock | 1,100 | $626.47 | $689,122.17 |
DisclosureSEC source: 0001567619-21-019740 · doc1.xml · nonDerivative · entry 3 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,916.6426 F3 · price: This transaction was executed in multiple trades at prices ranging from $626.10 to $627.005. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 08, 2021 Filed Nov 10, 2021 22:31 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
SaleCommon Stock | 1,300 | $625.25 | $812,824.09 |
DisclosureSEC source: 0001567619-21-019740 · doc1.xml · nonDerivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,016.6426 F2 · price: This transaction was executed in multiple trades at prices ranging from $625.00 to $625.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 08, 2021 Filed Nov 10, 2021 22:31 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
Exercise / conversionCommon Stock | 10,000 | $67.85 | $678,500.00 |
DisclosureSEC source: 0001567619-21-019740 · doc1.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,316.6426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 9 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on September 30, 2021. Read SEC document |
| October 29, 2021 Filed Nov 2, 2021 21:01 UTC |
JUNIUS DANIEL MDirector
|
GrantCommon Stock | 10 | $666.14 | $6,661.40 |
DisclosureSEC source: 0001567619-21-019216 · doc1.xml · nonDerivative · entry 1 JUNIUS DANIEL M · CIK 0001094159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,906 F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($6,562.50) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan. Read SEC document |
| October 29, 2021 Filed Nov 2, 2021 21:00 UTC |
COLLINS AshaDirector
|
GrantCommon Stock | 30 | $666.14 | $19,984.20 |
DisclosureSEC source: 0001567619-21-019214 · doc1.xml · nonDerivative · entry 1 COLLINS Asha · CIK 0001832272 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137 F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($20,000.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan. Read SEC document |
| October 29, 2021 Filed Nov 2, 2021 21:00 UTC |
ESSIG STUARTDirector
|
GrantCommon Stock | 36 | $666.14 | $23,981.04 |
DisclosureSEC source: 0001567619-21-019215 · doc1.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,100 F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($23,750.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan. Read SEC document |
| October 11, 2021 Filed Oct 13, 2021 21:01 UTC |
Claflin Bruce L.Director
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 1,921 | Not disclosed Strike: $160.28 | Not disclosed |
DisclosureSEC source: 0001567619-21-018262 · doc1.xml · derivative · entry 2 Claflin Bruce L. · CIK 0001403694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,921 shares Expires 2027-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vested in one installment on May 3, 2018. Read SEC document |
| October 11, 2021 Filed Oct 13, 2021 21:01 UTC |
Claflin Bruce L.Director
|
Exercise / conversionCommon Stock | 1,921 | $160.28 | $307,897.88 |
DisclosureSEC source: 0001567619-21-018262 · doc1.xml · nonDerivative · entry 1 Claflin Bruce L. · CIK 0001403694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,921 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:01 UTC |
Smith Martin AlexanderExecutive Vice President
|
GrantRestricted Stock Unit · Derivative | 74 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-016750 · doc1.xml · derivative · entry 3 Smith Martin Alexander · CIK 0001621358 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74 Underlying: Common Stock · 74 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning September 1, 2021. F3 · price: Not applicable. F2 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning September 1, 2021. F2 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning September 1, 2021. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:01 UTC |
Smith Martin AlexanderExecutive Vice President
|
GrantIncentive Stock Option (right-to-buy) · Derivative | 588 | Not disclosed Strike: $690.70 | Not disclosed |
DisclosureSEC source: 0001567619-21-016750 · doc1.xml · derivative · entry 2 Smith Martin Alexander · CIK 0001621358 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 588 Underlying: Common Stock · 588 shares Expires 2031-08-31 F3 · price: Not applicable. F1 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning September 1, 2022. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:01 UTC |
Smith Martin AlexanderExecutive Vice President
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 124 | Not disclosed Strike: $690.70 | Not disclosed |
DisclosureSEC source: 0001567619-21-016750 · doc1.xml · derivative · entry 1 Smith Martin Alexander · CIK 0001621358 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124 Underlying: Common Stock · 124 shares Expires 2031-08-31 F3 · price: Not applicable. F1 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning September 1, 2022. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 21:03 UTC |
Turner Kathy VSenior Vice President
|
Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 1,256 | Not disclosed Strike: $79.54 | Not disclosed |
DisclosureSEC source: 0001567619-21-016671 · doc1.xml · derivative · entry 3 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,256 shares Expires 2025-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 628 shares on February 14, 2020, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 21:03 UTC |
Turner Kathy VSenior Vice President
|
Exercise / conversionCommon Stock | 1,256 | $79.54 | $99,902.24 |
DisclosureSEC source: 0001567619-21-016671 · doc1.xml · nonDerivative · entry 1 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,131.3869 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2021 Filed Jan 4, 2022 22:01 UTC |
AYERS JONATHAN WDirector
|
GiftCommon Stock | 6,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-000276 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 638,326 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.